Skip to content
WorldBrand.AI

Lyell Immunopharma

Corporate brand

UnclaimedRequest correction

Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer.

Last updated September 1, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer. The company is building an industry-leading pipeline based on deep understanding of T-cell biology and its interaction with cancer. It owns and operates the LyFE Manufacturing Center in Bothell, Washington, capable of manufacturing more than 1,200 patient CAR T-cell products a year at full capacity. The company was founded by cell therapy pioneers, and its leadership team includes industry veterans.

History

Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer. The company is building an industry-leading pipeline based on deep understanding of T-cell biology and its interaction with cancer. It owns and operates the LyFE Manufacturing Center in Bothell, Washington, capable of manufacturing more than 1,200 patient CAR T-cell products a year at full capacity. The company was founded by cell therapy pioneers, and its leadership team includes industry veterans.

Recent events

  • Lyell appoints Richard Sherry as senior vice president[5]

    Reported:

    Lyell Immunopharma announced Richard Sherry's appointment as Senior Vice President, TIL Specialist and Clinical Lead.

  • Sonoma Biotherapeutics raises $40 million in Series A funding[6]

    Reported:

    Sonoma Biotherapeutics launched with $40 million in Series A financing from an investor syndicate that included Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures and 8VC.

  • Sonoma Biotherapeutics and Lyell Immunopharma enter strategic partnership[6]

    Reported:

    Sonoma Biotherapeutics entered into a strategic partnership with Lyell Immunopharma, providing both parties access to technologies and know-how to enhance cell therapies in their respective areas of focus.

Sources7 sources

  1. 1Next-Generation CAR-T Cell Therapies for Cancer | Lyelllyell.com
  2. 2Clinical-stage Cell Therapy Company | About Lyelllyell.com
  3. 3Our Leadership | Lyelllyell.com
  4. 4Lyell Immunopharma (United States)wikidata.org
  5. 5Lyell任命Richard Sherry为高级副总裁prnewswire.com
  6. 6Sonoma Biotherapeutics完成4000万美元A轮融资prnewswire.com
  7. 7Sonoma Bio debuts with $40M to push Treg treatments for autoimmune, neuro diseasesfiercebiotech.com

Cite this profile: Cite the canonical profile. /brand-wiki/lyell-immunopharma · Editorial policy · How profiles are compiled